MedPath

Crossignal Therapeutics, Inc.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumor, Adult
Colorectal Cancer
Pancreatic Ductal Adenocarcinoma
Interventions
First Posted Date
2024-09-19
Last Posted Date
2024-11-04
Lead Sponsor
Crossignal Therapeutics, Inc.
Target Recruit Count
78
Registration Number
NCT06598007
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.